Article Sidebar

Published: 2022-11-30
Abstract Views: 107
DOI: https://doi.org/10.52163/yhc.v63i8.519
Issue
Vol. 63 No. chuyên đề 3-HN Sản Nhi Nghệ An (2022)
Section
Articles
How to Cite
Nhân, L. N. T. ., Thúy, N. T. T. ., Linh, N. Q. ., Khánh, T. V. ., Thịnh, T. H. ., Văn, T. T. ., & Tiến, N. V. . (2022). BRCA1/2 MUTATIONS IN PATIENTS WITH HEREDITARY BREAST - OVARIAN CANCER SYNDROME. Vietnam Journal of Community Medicine, 63(chuyên đề 3-HN Sản Nhi Nghệ An). https://doi.org/10.52163/yhc.v63i8.519

BRCA1/2 MUTATIONS IN PATIENTS WITH HEREDITARY BREAST - OVARIAN CANCER SYNDROME

Le Nguyen Trong Nhan1, Nguyen Thi Thu Thuy2, Nguyen Quy Linh2, Tran Van Khanh2, Tran Huy Thinh2, Ta Thanh Van2, Nguyen Viet Tien2
1 Ca Mau Hospital of Obstetrics and Pediatrics
2 Hanoi Medical University

Main Article Content

Abstract

Individuals with BRCA1/2 gene mutations are at increased risk of breast and ovarian cancer.
The prevalence of BRCA1/2 mutations varies by race and ethnicity. The prevalence and the risks
associated with most BRCA1/2 mutations has not been unknown in the Vietnamese population. We
herein screen the entire BRCA1 and BRCA2 genes for breast and ovarian cancer patients with
Hereditary Breast - Ovarian Cancer Syndrome (HBOC), thereby, suggesting personalized
evaluation risk of mutation carrier, breast and ovarian cancer and personalized plan of cancers
screening and prevention.
Objects: 33 patients who had a pathological diagnosis of breast and/or ovarian cancer with
HBOC syndrome.
Methods: Cross-sectional descriptive. Blood samples of 33 patients were collected and
analyzed using Next Generation Sequencing. The identified mutations were tested by Sanger
sequencing. Identification of mutations in the family members of patients carrying the mutation.
Results: Eleven types of mutations in both BRCA1 (in nine patients) and BRCA2 (in three
patients) were detected, one of which (BRCA2:p.Ser1341Ter) is novel, unpublished. Seven out of
19 patient’s relatives had BRCA1/2 gene mutations. All patients were counselled about the
likelihood of cancer rising and prophylactic screening and procedures. Conclusions: Our findings
suggested the implications for the planning of a screening programme for BRCA1 and BRCA2
genes testing in breast and ovarian cancer patients and genetic screening in their relatives.

Article Details

Keywords

BRCA1; BRCA2; UT vú và buồng trứng di truyền.

References

1. Sung H, Global Cancer Statistics 2020:
GLOBOCAN Estimates of Incidence and
Mortality Worldwide for 36 Cancers in 185
Countries. CA Cancer J Clin, 2021. 71(3): p.
209-249.
2. Neff RT, Senter L, Salani R, BRCA
mutation in ovarian cancer: testing, implications
and treatment considerations. Ther Adv Med
Oncol, 2017. 9(8): p. 519-531.
3. Finch AP, Impact of oophorectomy on
cancer incidence and mortality in women with a
BRCA1 or BRCA2 mutation. J Clin Oncol,
2014.32(15): p. 1547-53.
4. Petrucelli N, Daly MB, PT, BRCA1- and
BRCA2-Associated Hereditary Breast and
Ovarian Cancer. GeneReviews® [Internet]
University of Washington, Seattle, 1998 Sep 4
[Updated 2016 Dec 15]. In: Adam MP, Ardinger
HH, Pagon RA, et al. 1993-2021.
5. Myriad_Genetic_Laboratories. The
Prevalence of Deleterious Mutations in BRCA1
and BRCA2. Mutation Prevalence Tables 2010;
Available from:
https://s3.amazonaws.com/myriadlibrary/brac/brca-prevalence-tables.pdf.
6. Cline MS, BRCA Challenge: BRCA
Exchange as a global resource for variants in
BRCA1 and BRCA2. PLoS Genet, 2018. 14(12):
p. e1007752.
7. Frank TS, Clinical characteristics of
individuals with germline mutations in BRCA1
and BRCA2: analysis of 10,000 individuals. J
Clin Oncol, 2002. 20(6): p. 1480-90.
8. Daly MB, Genetic/Familial High-Risk
Assessment: Breast, Ovarian, and Pancreatic,
Version 2.2021, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc
Netw, 2021. 19(1): p. 77-102.
9. Carver T, CanRisk Tool-A Web Interface
for the Prediction of Breast and Ovarian Cancer
Risk and the Likelihood of Carrying Genetic
Pathogenic Variants. Cancer Epidemiol
Biomarkers Prev, 2021. 30(3): p. 469-473.